Please enable JavaScript to continue using this application.

Compare $CYTK vs $KYMR | Chartloom

Compare

$CYTK vs $KYMR

Cytokinetics Inc · Kymera Therapeutics Inc

CYTK

Cytokinetics Inc

KYMR

Kymera Therapeutics Inc

Compare $CYTK vs $KYMR

Comparing Cytokinetics Inc and Kymera Therapeutics Inc

CYTKCytokinetics Inc

KYMRKymera Therapeutics Inc

CYTKCytokinetics Inc

Market cap

$8.53B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

33.61x

Rev growth (TTM)

-21.1%

YTD performance

1.9%

52W performance

3.4%

FCF yield

-6.8%

KYMRKymera Therapeutics Inc

Market cap

$9.25B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

456.91x

Rev growth (TTM)

134.8%

YTD performance

54.5%

52W performance

99.7%

FCF yield

-2.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CYTK

KYMR

Detailed metrics comparison

CYTK

Cytokinetics Inc

KYMR

Kymera Therapeutics Inc

Market Cap

CYTK$8.53B

KYMR$9.25B

Enterprise Value

CYTK$9.42B

KYMR$9.12B

Price

CYTK$62.91

KYMR$112.40

P/E Ratio

CYTKN/A

KYMRN/A

P/S Ratio

CYTK126.04x

KYMR88.06x

EV/Sales

CYTK139.22x

KYMR86.90x

EV/EBITDA

CYTK1,193.30x

KYMR0.00x

P/B Ratio

CYTK83.67x

KYMR5.92x

P/FCF Ratio

CYTKN/A

KYMRN/A

EV/FCF

CYTK-16.22x

KYMR-38.34x

PEG Ratio

CYTKN/A

KYMRN/A

Forward P/E (NTM)

CYTKN/A

KYMRN/A

Forward P/S (NTM)

CYTK33.61x

KYMR456.91x

Revenue (TTM)

CYTK$68M

KYMR$105M

Revenue Growth (YoY)

CYTK-21.1%

KYMR134.8%

Forward Rev Growth

CYTK183.7%

KYMR-62.1%

Gross Margin (TTM)

CYTK58.9%

KYMR0.0%

Operating Margin (TTM)

CYTK0.0%

KYMR0.0%

EBITDA Margin (TTM)

CYTK-1027.6%

KYMR-322.0%

Net Margin (TTM)

CYTK-1321.1%

KYMR-285.3%

FCF Margin (TTM)

CYTK-858.2%

KYMR-226.6%

Net Income (TTM)

CYTK$-894M

KYMR$-300M

FCF (TTM)

CYTK$-581M

KYMR$-238M

EPS (TTM)

CYTK-$6.77

KYMR-$3.05

ROE (TTM)

CYTK-13119.0%

KYMR-2150.0%

ROA (TTM)

CYTK-5902.0%

KYMR-1946.0%

ROIC (TTM)

CYTK-1872.0%

KYMR-2145.0%

Cash

CYTK$255M

KYMR$124M

Debt

CYTK$1.15B

KYMR$2M

Net Cash/Debt

CYTK$-892M

KYMR$122M

Current Ratio (TTM)

CYTK6.66x

KYMR10.34x

Quick Ratio (TTM)

CYTK6.56x

KYMR9.97x

Debt/Equity (TTM)

CYTK6.01x

KYMR0.00x

Debt/Assets (TTM)

CYTK0.0%

KYMR0.0%

Interest Coverage (TTM)

CYTKN/A

KYMRN/A

Net Debt/EBITDA (TTM)

CYTK0.00x

KYMR0.00x

Beta

CYTK0.42

KYMR2.05

52W Performance

CYTK3.4%

KYMR99.7%

YTD Performance

CYTK1.9%

KYMR54.5%

% from 52W High

CYTK-28.8%

KYMR-13.6%

% from 52W Low

CYTK15.9%

KYMR103.4%

Asset Turnover (TTM)

CYTK0.04x

KYMR0.07x

FCF Yield (TTM)

CYTK-6.8%

KYMR-2.6%

Earnings Yield (TTM)

CYTK-10.5%

KYMR-3.2%

Dividend Yield (TTM)

CYTKN/A

KYMRN/A

Rule of 40

CYTK-879.2

KYMR-91.8

EV/GP/RG

CYTK0.73

KYMRN/A

Ticker research

View CYTK research View KYMR research

Metric	CYTK Cytokinetics Inc	KYMR Kymera Therapeutics Inc
Market & Valuation
Market Cap	$8.53B	$9.25B
Enterprise Value	$9.42B	$9.12B
Price	$62.91	$112.40
P/E Ratio	N/A	N/A
P/S Ratio	126.04x	88.06x
EV/Sales	139.22x	86.90x
EV/EBITDA	1,193.30x	0.00x
P/B Ratio	83.67x	5.92x
P/FCF Ratio	N/A	N/A
EV/FCF	-16.22x	-38.34x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	33.61x	456.91x
Revenue & Growth
Revenue (TTM)	$68M	$105M
Revenue Growth (YoY)	-21.1%	134.8%
Forward Rev Growth	183.7%	-62.1%
Profitability
Gross Margin (TTM)	58.9%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1027.6%	-322.0%
Net Margin (TTM)	-1321.1%	-285.3%
FCF Margin (TTM)	-858.2%	-226.6%
Net Income (TTM)	$-894M	$-300M
FCF (TTM)	$-581M	$-238M
EPS (TTM)	-$6.77	-$3.05
ROE (TTM)	-13119.0%	-2150.0%
ROA (TTM)	-5902.0%	-1946.0%
ROIC (TTM)	-1872.0%	-2145.0%
Financial Health
Cash	$255M	$124M
Debt	$1.15B	$2M
Net Cash/Debt	$-892M	$122M
Current Ratio (TTM)	6.66x	10.34x
Quick Ratio (TTM)	6.56x	9.97x
Debt/Equity (TTM)	6.01x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.42	2.05
52W Performance	3.4%	99.7%
YTD Performance	1.9%	54.5%
% from 52W High	-28.8%	-13.6%
% from 52W Low	15.9%	103.4%
Efficiency & Yields
Asset Turnover (TTM)	0.04x	0.07x
FCF Yield (TTM)	-6.8%	-2.6%
Earnings Yield (TTM)	-10.5%	-3.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-879.2	-91.8
EV/GP/RG	0.73	N/A
Ticker research	View CYTK research	View KYMR research

Valuation

P/S Ratio

KYMR

88.06x

CYTK

126.04x

EV/FCF

KYMR

-38.34x

CYTK

-16.22x

Growth & revenue

Revenue Growth TTM

KYMR

134.8%

CYTK

-21.1%

Forward Revenue Growth

CYTK

183.7%

KYMR

-62.1%

Profitability & performance

Gross Margin

CYTK

58.9%

KYMR

0.0%

ROE

KYMR

-2150.0%

CYTK

-13119.0%

FCF Yield %

KYMR

-2.6%

CYTK

-6.8%

52-Week Performance

KYMR

99.7%

CYTK

3.4%

Detailed metrics comparison

CYTK

Cytokinetics Inc

KYMR

Kymera Therapeutics Inc

Market Cap

CYTK$8.53B

KYMR$9.25B

Enterprise Value

CYTK$9.42B

KYMR$9.12B

Price

CYTK$62.91

KYMR$112.40

P/E Ratio

CYTKN/A

KYMRN/A

P/S Ratio

CYTK126.04x

KYMR88.06x

EV/Sales

CYTK139.22x

KYMR86.90x

EV/EBITDA

CYTK1,193.30x

KYMR0.00x

P/B Ratio

CYTK83.67x

KYMR5.92x

P/FCF Ratio

CYTKN/A

KYMRN/A

EV/FCF

CYTK-16.22x

KYMR-38.34x

PEG Ratio

CYTKN/A

KYMRN/A

Forward P/E (NTM)

CYTKN/A

KYMRN/A

Forward P/S (NTM)

CYTK33.61x

KYMR456.91x

Revenue (TTM)

CYTK$68M

KYMR$105M

Revenue Growth (YoY)

CYTK-21.1%

KYMR134.8%

Forward Rev Growth

CYTK183.7%

KYMR-62.1%

Gross Margin (TTM)

CYTK58.9%

KYMR0.0%

Operating Margin (TTM)

CYTK0.0%

KYMR0.0%

EBITDA Margin (TTM)

CYTK-1027.6%

KYMR-322.0%

Net Margin (TTM)

CYTK-1321.1%

KYMR-285.3%

FCF Margin (TTM)

CYTK-858.2%

KYMR-226.6%

Net Income (TTM)

CYTK$-894M

KYMR$-300M

FCF (TTM)

CYTK$-581M

KYMR$-238M

EPS (TTM)

CYTK-$6.77

KYMR-$3.05

ROE (TTM)

CYTK-13119.0%

KYMR-2150.0%

ROA (TTM)

CYTK-5902.0%

KYMR-1946.0%

ROIC (TTM)

CYTK-1872.0%

KYMR-2145.0%

Cash

CYTK$255M

KYMR$124M

Debt

CYTK$1.15B

KYMR$2M

Net Cash/Debt

CYTK$-892M

KYMR$122M

Current Ratio (TTM)

CYTK6.66x

KYMR10.34x

Quick Ratio (TTM)

CYTK6.56x

KYMR9.97x

Debt/Equity (TTM)

CYTK6.01x

KYMR0.00x

Debt/Assets (TTM)

CYTK0.0%

KYMR0.0%

Interest Coverage (TTM)

CYTKN/A

KYMRN/A

Net Debt/EBITDA (TTM)

CYTK0.00x

KYMR0.00x

Beta

CYTK0.42

KYMR2.05

52W Performance

CYTK3.4%

KYMR99.7%

YTD Performance

CYTK1.9%

KYMR54.5%

% from 52W High

CYTK-28.8%

KYMR-13.6%

% from 52W Low

CYTK15.9%

KYMR103.4%

Asset Turnover (TTM)

CYTK0.04x

KYMR0.07x

FCF Yield (TTM)

CYTK-6.8%

KYMR-2.6%

Earnings Yield (TTM)

CYTK-10.5%

KYMR-3.2%

Dividend Yield (TTM)

CYTKN/A

KYMRN/A

Rule of 40

CYTK-879.2

KYMR-91.8

EV/GP/RG

CYTK0.73

KYMRN/A

Ticker research

View CYTK research View KYMR research

Metric	CYTK Cytokinetics Inc	KYMR Kymera Therapeutics Inc
Market & Valuation
Market Cap	$8.53B	$9.25B
Enterprise Value	$9.42B	$9.12B
Price	$62.91	$112.40
P/E Ratio	N/A	N/A
P/S Ratio	126.04x	88.06x
EV/Sales	139.22x	86.90x
EV/EBITDA	1,193.30x	0.00x
P/B Ratio	83.67x	5.92x
P/FCF Ratio	N/A	N/A
EV/FCF	-16.22x	-38.34x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	33.61x	456.91x
Revenue & Growth
Revenue (TTM)	$68M	$105M
Revenue Growth (YoY)	-21.1%	134.8%
Forward Rev Growth	183.7%	-62.1%
Profitability
Gross Margin (TTM)	58.9%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1027.6%	-322.0%
Net Margin (TTM)	-1321.1%	-285.3%
FCF Margin (TTM)	-858.2%	-226.6%
Net Income (TTM)	$-894M	$-300M
FCF (TTM)	$-581M	$-238M
EPS (TTM)	-$6.77	-$3.05
ROE (TTM)	-13119.0%	-2150.0%
ROA (TTM)	-5902.0%	-1946.0%
ROIC (TTM)	-1872.0%	-2145.0%
Financial Health
Cash	$255M	$124M
Debt	$1.15B	$2M
Net Cash/Debt	$-892M	$122M
Current Ratio (TTM)	6.66x	10.34x
Quick Ratio (TTM)	6.56x	9.97x
Debt/Equity (TTM)	6.01x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.42	2.05
52W Performance	3.4%	99.7%
YTD Performance	1.9%	54.5%
% from 52W High	-28.8%	-13.6%
% from 52W Low	15.9%	103.4%
Efficiency & Yields
Asset Turnover (TTM)	0.04x	0.07x
FCF Yield (TTM)	-6.8%	-2.6%
Earnings Yield (TTM)	-10.5%	-3.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-879.2	-91.8
EV/GP/RG	0.73	N/A
Ticker research	View CYTK research	View KYMR research